Kornimate/medical-research-clean huggingface dataset:
image fusion of preprocedural cta with real time fluoroscopy to enhance evar repair

Conditions: Abdominal Aortic Aneurysm (AAA)

Summary: abdominal aortic aneurysm (aaa) is a potentially life threatening condition. if the aneurysm ruptures, the mortality can be as high as 80%. endovascular aneurysms repair (evar) is a minimal invasive procedure and has been widely used on treating aaa. advanced endovascular techniques are used to treat patients with more complex pathology by using custom-made devices and additional stents. in order to accomplish the technical success on advanced evar, with the current imaging equipment and technique for evar procedures (i.e. live x-ray fluoroscopy and 2-d digital subtraction angiography (dsa)), multiple angiograms on the target arteries (arteriograms) are required. subsequently patients are exposed to higher dose of contrast and radiation, compared to conventional evar. this study is to assess the feasibility of proper visceral and renal arteries catheterization using a 3d model obtained from pre-procedural computed tomographic angiography (cta), fused with real-time fluoroscopy, without contrast injection or angiographic run-offs thus minimizing the contrast use and patient radiation exposure while achieving procedure success during advanced evar.


Eligibility criteria:
inclusion criteria: * male or female \>= 18 years; * scheduled for advanced evar for abdominal aortic aneurysm. exclusion criteria: * pregnancy;
motor performance in children with attention deficit hyperactivity disorder

Conditions: Attention Deficit Hyperactivity Disorder

Summary: attention deficit hyperactivity disorder (adhd) is one of the most common neurodevelopmental disorders in children. children with adhd have difficulties with co-contraction, producing muscle force, and regulating movement velocity, and physical fitness. the purpose of this study was to compare the gross and fine motor abilities in children with adhd and children with typical development.

attention deficit hyperactivity disorder (adhd) is one of the most common neurodevelopmental disorders in children worldwide with a prevalence of 2.6-4.5% between the ages of 6 and 18 years. when compared to children with typical development, children with adhd have lower scores in 9-12% of gross motor abilities, 9-36% of balance and postural control, 9-19% of fine motor abilities, and 19-22 % of manual and body coordination. furthermore, children with adhd have difficulties with co-contraction, producing muscle force, and regulating movement velocity, and physical fitness. as a consequence of the core symptoms of adhd, such as inattention, impulsivity, and hyperactivity, over 30-50% of children with adhd may have impaired motor ability. the purpose of this study was to compare the gross and fine motor abilities in children with adhd and children with typical development.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of children with attention deficit hyperactivity disorder * aged at 6 -15 years old * able to understand and accept verbal instructions. exclusion criteria: * clinical diagnosis of children with another psychiatric including autism spectrum disorder, psychotic symptoms, depression * clinical diagnosis of children with neurological disorder including cerebral palsy, epilepsy, or speech impairments * the parents declined to participate in the study.

Keywords: attention deficit hyperactivity disorder motor skills children
testosterone replacement in diabetes with vascular disease (version 2)

Conditions: Diabetes Mellitus; Peripheral Vascular Disease

Summary: diabetes is a major cause of peripheral vascular disease(pvd) and is associated with male hypogonadism. diabetes and pvd are both associated with arterial stiffness and intima -media thickness which are also related to severity of the clinical syndrome of pvd. artificially induced hypogonadism results in increasing arterial stiffness whilst testosterone is known to improve risk factors for vascular disease and act as a vasodilator. the purpose of this pilot study is to assess the effect of testosterone treatment on pvd arterial stiffness and intima-media thickness in men with type 2 diabetes and hypogonadism,


Eligibility criteria:
inclusion criteria: * male patients greater than 18 years of age * type 2 diabetes mellitus * serum testosterone less than 11 nmol/l on two consecutive samples taken on different days * peripheral vascular disease as defined by abpi less than 0.92 and ischaemic leg pain (claudication or rest pain) or distal complications (non-healing arterial foot ulcer or gangrene * agreement to maintain antihypertensive and anti-lipid treatments at prior doses during 3 months of study * ability to give written informed consent after verbal and written explanation in the english language * ability to comply with all study requirements exclusion criteria: * current or previous breast cancer * current or previous prostate cancer * raised prostate specific antigen or abnormal per rectal examination unless prostate cancer excluded after specialist urology opinion * severe symptoms of benign prostatic hypertrophy ('prostatism') * treatment with testosterone in the 3 months prior to the trial * investigational drug treatment in the 3 months prior to the trial
effect of anesthesia on expression of programmed death-1 and programmed death-1 ligand in breast cancer

Conditions: Programmed Cell Death 1

Summary: surgery is first-line treatment for solid tumors. however, surgical trauma-induced physiologic stress has been demonstrated to facilitate metastasis and recurrence in different types of cancer. it has been reported that the pd-1/pd-l1 pathway could be activated by surgical stress. hence, we instigate the effect of anesthetic technique on expression of pd1 and pd1 ligand.

the cellular immune response plays a central part in postoperative clearance of tumor cells. t lymphocytes and natural killer (nk) cells are two predominant cytotoxic effector cells that are the major components of antitumor immunity. in mouse models, proliferation of t lymphocytes in response to surgical trauma is defective . programmed death-1 (pd-1) belongs to the cd28 receptor superfamily. it is an inhibitory receptor, and its expression is upregulated on activated leukocytes, resulting in an inhibited immune response. pd-1 interacts with two ligands: programmed death ligand-1 (pd-l1, also referred to as b7-h1) and programmed death ligand-2 (pd-l2, also known as b7-dc). pd-l2 is expressed mainly on activated dendritic cells (dcs) and macrophages, whereas pd-l1 is distributed widely. in addition to immune cells, some subsets of tumor cells also express pd-l1 to escape from immunosurveillance. it has been reported that the pd-1/pd-l1 pathway could be activated by surgical stress. hence, we instigate the effect of anesthetic technique on expression of pd1 and pd1 ligand.

Eligibility criteria:
inclusion criteria: * patients scheduled for breast cancer surgery exclusion criteria: * compromised immune function (such as infection with the human immunodeficiency virus, immunodeficiency, or treatment with corticosteroids, immunosuppressive drugs, or chemotherapy) * asa \> iii * age\> 70 years old. * patients refusal to the procedure. * infection of the skin at or near site of needle puncture. * coagulopathy . * drug hypersensitivity or allergy to the studied drugs. * central or peripheral neuropthy . * pre-operative opoid consumption ( within 24 hours preoperative ) * anomalies of the vertebral column .

Keywords: brest cancer programmed cell death1 programmed cell death ligand 1
registry study on biological disease profile and clinical outcome in patients with newly diagnosed or existent lung cancer the luca biology and outcome (bio)-project

Conditions: Lung Cancer

Summary: registry study on biological disease profile and clinical outcome in patients with newly diagnosed or existent lung cancer the luca biology and outcome (bio)-project


Eligibility criteria:
inclusion criteria: * patients with suspected diagnosis of lung cancer, or previously diagnosed lung cancer * age ≥ 18 years. there is no upper age limit. exclusion criteria: * severe neurological or psychiatric disorder interfering with ability to give an informed consent * no consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation * no consent for biobanking of patient's biological specimens and performance of analyses on stored material.

Keywords: lung cancer registry study biological disease profile
a safety and efficacy study of xyrem® in subjects with fibromyalgia

Conditions: Fibromyalgia

Summary: the objective of this trial is to evaluate the safety and efficacy of xyrem® compared to placebo for the treatment of fibromyalgia in a randomized, double blind, placebo controlled, parallel group trial.

the trial is a randomized, double blind, placebo controlled, parallel group trial in subjects diagnosed with fibromyalgia in accordance with the american college of rheumatology. total duration is up to twenty-one (21) weeks of trial participation. subjects will undergo a screening and withdrawal/washout period lasting up to five (5) weeks combined, followed by baseline period lasting one (1) week. total treatment duration will be fourteen (14) weeks followed by one (1) week safety follow-up post treatment period. during the screening and withdrawal/washout period, no study medication will be given; however rescue medication acetaminophen (up to 4 grams per day) will be allowed.

Eligibility criteria:
inclusion criteria: * male or female subjects, 18 years or older who meet the american college of rheumatology (acr) diagnostic criteria for fibromyalgia. exclusion criteria: * subjects will be excluded if they have a history of rheumatic disease or other disorders that may compromise reliable representation of subjective symptoms. * any other condition that will cause a risk to subjects if they participate in the trial is also a reason for exclusion.

Keywords: fms fibro pain body pain tenderness joint pain stiffness muscular pain
team-based ergonomics educational model for workplace wellness improvement: a pilot study

Conditions: MSDs; Muscle Pain

Summary: this research is being done to explore the potential benefit of a physical therapist-guided stretching program on musculoskeletal pain and well-being.


Eligibility criteria:
inclusion criteria: * hmc/com staff (faculty, residents, fellows, apps, physical/occupational therapists, nurses, schedulers, etc.) * at least 18 years old * willing and able to participate in all study procedures * willing and able to provide informed consent * group 2 subjects must have access to a computer with internet or an iphone or android smartphone exclusion criteria: * subjects who do not meet all inclusion criteria will be excluded from the study.
tryptophan metabolism in kidney disease

Conditions: Chronic Kidney Disease

Summary: tryptophan metabolism in kidney disease will be investigated in patients with chronic kidney disease stages (adoqi 3-5). tryptophan levels and respective catabolites will be assessed under hemodialysis.


Eligibility criteria:
inclusion criteria: * chronic kidney disease (for \> 3months) stages (national kidney foundation/adoqi): 3-5 exclusion criteria: * signs of infection or systemic inflammation

Keywords: assessment of tryptophan and tryptophan catabolites and ido-activity in patients with chronic kidney disease
an expanded access program of emicizumab in participants with hemophilia a with inhibitors

Conditions: Hemophilia A

Summary: this open-label, multicenter expanded access program (eap) is designed to provide emicizumab to eligible participants with hemophilia a with factor viii (fviii) inhibitors before it is commercially available in the united states for the indication of hemophilia a with fviii inhibitors. discontinuation may occur earlier if participant or physician decides to discontinue treatment or the sponsor discontinues emicizumab clinical development.


Eligibility criteria:
inclusion criteria: * diagnosis of congenital hemophilia a of any severity and documented history of high-titer inhibitor (that is \[i.e.\], greater than or equal to \[\>/=\] 5 bethesda units) * history of treatment with episodic or prophylactic bypassing agents for at least the last 24 weeks * \>/=6 (if on an episodic bypassing agent regimen) or \>/=2 (if on a prophylactic bypassing agent regimen) bleeds within 24 weeks prior to screening * currently using recombinant activated factor vii (rfviia) or are willing to switch to rfviia as primary bypassing agent for the treatment of breakthrough bleeds * adequate hematologic function, defined as platelet count \>/= 100,000 per microliters (mcl) and hemoglobin \>/=8 grams per deciliter (g/dl) at screening * adequate hepatic and renal function exclusion criteria: * inherited or acquired bleeding disorder other than hemophilia a * ongoing (or plan to receive during the study) immune tolerance induction (iti) therapy or prophylaxis with fviii with the exception of participants who have received a treatment regimen of fviii prophylaxis with concurrent bypassing agent prophylaxis * treatment for thromboembolic disease within 12 months before day 1 (with the exception of previous catheter-associated thrombosis for which antithrombotic treatment is not currently ongoing) or current signs of thromboembolic disease * other conditions (example \[e.g.\], certain autoimmune diseases) that may increase the risk of bleeding or thrombosis * high risk for thrombotic microangiopathy (tma), in the investigator's judgment * history of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection * use of systemic immunomodulators (e.g., interferon or rituximab) at enrollment or planned use during the study, with the exception of antiretroviral therapy * treatment with any of the following: an investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration before day 1; a non-hemophilia-related investigational drug within the last 30 days or 5 half-lives before day 1, whichever is longer; an investigational drug concurrently * any serious medical condition, treatment, or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in the study
fludarabine and total body irradiation 800 centigray (cgy) or 1125 cgy for allogeneic stem cell transplant using graft versus host disease prophylaxis with post-transplant cyclophosphamide and tacrolimus, without mycophenolate mofetil

Conditions: Hematologic Neoplasms

Summary: this is a pilot study to evaluate the feasibility, safety and potential benefits of removing one immune suppressive drug called mycophenolate mofetil (mmf) from the standard allogenic stem cell transplant treatment protocol. mmf will be omitted from the transplant regimen in 60 eligible patients with hematologic malignancies. participants will be followed for up to 2 years post standard of care transplant at cedars-sinai.


Eligibility criteria:
inclusion criteria: * patient age 18-75 years * patient has a related donor who is at least human leukocyte antigen (hla) haploidentical, or an unrelated donor who is a most a single hla antigen mismatch. * patient signs the informed consent form for the study * patient has a hematologic malignancy other than myelofibrosis and meets standard criteria for allogeneic stem cell transplant. * patient is deemed suitable to receive fludarabine and total body irradiation (flu/tbi) 1125 or flu/tbi 800 conditioning regimen as standard of care transplant * donor is willing to donate peripheral blood stem cells exclusion criteria: * patient has a diagnosis of myelofibrosis * patient has high titer antibodies against one or more donor hla antigens * patient has undergone prior autologous or allogeneic stem cell transplant. * inability to collect sufficient peripheral blood stem cells from the donor

Keywords: allogeneic stem cell transplant
hypothermia in the trauma patient - when do trauma patients get cold?

Conditions: Hypothermia

Summary: the purpose of this study is to analyze changes in core body- and skin temperature during pre-hospital and early in-hospital treatment of multi-traumatized patients. the researchers want to investigate when trauma patients get cold and to what extent.

hypothermia is a common finding in severely traumatized patients. decreases in core temperature during the course of initial evaluation and resuscitation are common, and can contribute to poor outcomes in multi-traumatized patients. in this study the temperature will be recorded continually with multiple skin probes and an ear-probe from the site of the accident to arrival in the intensive care unit (including time in primary surgery, if any).

Eligibility criteria:
inclusion criteria: * trauma patient with a iss 9 or above. exclusion criteria: * \<12 years old

Keywords: trauma patients severe injury iss ≥9
vitamin d replacement in bronchiectasis

Conditions: Bronchiectasis

Summary: this study seeks to address the limitations in previous related studies on vitamin d replacement and bronchiectasis exacerbation occurrence through a self-controlled pilot study. the investigators aim to investigate whether vitamin d replacement in bronchiectasis patients with vitamin d deficiency can reduce hospitalized bronchiectasis exacerbation occurrence. patients who participated in the prior study entitled "prospective clinical study on serum 25-hydroxyvitamin d (25-oh d) level and risk of bronchiectasis exacerbation" (uw 22-317) will be invited for participation during regular clinic follow-up and management in queen mary hospital. if participants are willing to join the further research, participants will be recruited in this self-controlled study. there are some differences from usual management to non-cf bronchiectasis subjects. the study subjects would be checked for their blood 25-hydroxyvitamin-d level during the study period. the non-cf bronchiectasis subjects with vitamin d deficiency would be given 1000 iu and 2000 iu (if needed). the investigators aim to correct their vitamin d deficiency completely, aiming at blood 25-hydroxyvitamin-d level \>=50, i.e. treat to target. the dose depends on the level of vitamin d after replacement. if blood 25-hydroxyvitamin-d level is 50 or above, then 1000 iu is suffice. if blood 25-hydroxyvitamin-d level is still below 50, the investigators will increase to 2000 iu.


Eligibility criteria:
inclusion criteria: 1. ages 18 years or above, male or female. 2. confirmed diagnosis of non-cf bronchiectasis based on high-resolution computed tomography (hrct) scan. 3. participation in the prior study entitled "prospective clinical study on serum 25-hydroxyvitamin d (25-oh d) level and risk of bronchiectasis exacerbation" (uw 22-317) exclusion criteria: 1. underlying asthma, copd and other co-existing respiratory diseases 2. underlying osteoporosis 3. supplementary vitamin d in their regimen 4. advanced chronic kidney disease with estimated glomerular filtration rate (egfr) \< 30ml/min
clinical study assessing the efficacy and safety of macitentan in fontan-palliated subjects

Conditions: Congenital Heart Disease

Summary: the primary objective is to assess the effect of macitentan 10 mg as compared to placebo on exercise capacity through cardiopulmonary exercise testing.


Eligibility criteria:
inclusion criteria: * written informed consent/assent from the subject and/or a legal representative prior to initiation of any study-mandated procedures * fontan-palliated subjects with either intra-atrial lateral tunnel total cavopulmonary connection (lt-tcpc), or extra cardiac tunnel tcpc (ec-tcpc) surgery \> 1 year before screening. either lt- or ec-tcpc can be primary or secondary to atrio-pulmonary connection * new york heart association (nyha) functional class (fc) ii or iii (assessed by the investigator using the specific activity scale * women of childbearing potential must have a negative serum pregnancy test use reliable contraception exclusion criteria: * pattern of fontan circulation severity * deterioration of the fontan-palliated condition. * limitations to cardiopulmonary exercise testing (cpet) * peak vo2 \< 15 ml/kg/min. * any known factor or disease that may interfere with treatment compliance or full participation in the study
implementing internet-assisted treatment for non-cardiac chest pain

Conditions: Chest Pain

Summary: this study aims to test implementation of internet-assisted treatment for non-cardiac chest pain at the cardiac department at sørlandet hospital. the internet-assisted treatment will be delivered by personnel working at the department. effectiveness will be tested in an randomized controlled trial (rct). the intervention has been tested in an rct where the intervention was delivered by a cognitive behavioral therapy (cbt) specialist who also participated in developing the intervention. presently the investigators will test if personnel working at the department, with minimal training in cbt, can deliver the intervention effectively.

most patients with chest pain referred to hospital do not have a cardiac illness. non-cardiac chest pain (nccp) is often followed by persistent distress and reduced quality of life, and societal costs are nearly equal to those of cardiac patients. research suggests that face-to-face cbt is effective, but this has not been implemented as standard treatment. the investigators plan to test an easily implementable internet-assisted treatment for nccp patients delivered by personnel already working at the department. patients will be recruited at the chest pain unit at sørlandet hospital, kristiansand, and will be recruited after they have finished their cardiac examination. the intervention group will receive six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment.

Eligibility criteria:
inclusion criteria: * non-cardiac chest pain exclusion criteria: * language difficulties * unable to perform at least moderate physical activity due to physical constraints * obvious cognitive impairment (e.g mentally retarded, psychotic, dementia or intoxicated) * no regular access to a computer/tablet computer with internet connection

Keywords: non-cardiac chest pain nccp anxiety internet-assisted treatment